Effects of Dexmedetomidine on Breast Cancer Cell Function in Vitro

NCT03108937 | Completed

• 1 other identifier: DEX201703
• Study Type: interventional
• Target: 24
• Locations: 1 country
• Sites: 1

Brief Summary

Dexmedetomidine is widely used as an anaesthetic for general anesthesia during surgery. Previous studies in cells and animals show that dexmedetomidine may promote cancer growth. Using serum from breast cancer surgery patients randomized to receive dexmedetomidine or saline during surgery, we investigated the effects of dexmedetomidine on proliferation, migration and metastasis in MCF-7 breast cancer cells in vitro.

Conditions

Breast Cancer

Outcome Measures

Primary Outcomes (1)

• cell proliferation

  MCF-7 cells will be cultured with serum from patients of both groups for 24 hours and cell proliferation will be measured

  24 hour post-surgery

Secondary Outcomes (2)

• cell migration

  24 hour post-surgery

• cell metastasis

  24 hour post-surgery

Study Arms (2)

Dexmedetomidine

EXPERIMENTAL

Patients of dexmedetomidine group will receive a loading does of 1ug/kg dexmedetomidine since 15 mins before induction, and receive another 1ug/kg of dexmedetomidine at a rate of 0.5ug/kg/h for 2 continuous hours during surgery.

Drug: Dexmedetomidine

saline

PLACEBO COMPARATOR

Same amount of saline will be administrated.

Drug: saline

Interventions

Dexmedetomidine DRUG

Patients in the experimental group will receive Dexmedetomidine during surgery.

Dexmedetomidine

saline DRUG

Patients in the control group will receive saline but not Dexmedetomidine during surgery.

saline

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• ASA grade I-III Age range of 18 to75 Patients diagnosed primary breast cancer(T2-3, N0-2, M0) Patients will have elective adenomammectomy

You may not qualify if:

• with history of breast operation Patients diagnosed carcinoma erysipelatodes Severe liver, renal, brain or lung disease with history of opioid addiction Patients diagnosed metastatic breast cancer

Sponsors & Collaborators

• RenJi Hospital: lead

Study Sites (1)

Renji Hospital

Shanghai, Shanghai Municipality, 200127, China

Location

Related Publications (1)

• Liu Y, Sun J, Wu T, Lu X, Du Y, Duan H, Yu W, Su D, Lu J, Tian J. Effects of serum from breast cancer surgery patients receiving perioperative dexmedetomidine on breast cancer cell malignancy: A prospective randomized controlled trial. Cancer Med. 2019 Dec;8(18):7603-7612. doi: 10.1002/cam4.2654. Epub 2019 Oct 30.

  PMID: 31663690 DERIVED

MeSH Terms

Conditions

Breast Neoplasms

Interventions

Dexmedetomidine; Sodium Chloride

Condition Hierarchy (Ancestors)

Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases; Skin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

Imidazoles; Azoles; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Chlorides; Hydrochloric Acid; Chlorine Compounds; Inorganic Chemicals; Sodium Compounds

Study Officials

• Jie Tian

  RenJi Hospital

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 6, 2017
• First Posted: April 11, 2017
• Study Start: April 12, 2017
• Primary Completion: July 7, 2017
• Study Completion: September 8, 2017
• Last Updated: October 10, 2017

Record last verified: 2017-03

Locations

CN (1)